Tests empagliflozin effects on heart and muscle energy in type 2 diabetes
Tests empagliflozin against placebo in adults with diabetes and heart failure.
Plain-language title generated from the registry record
Registry title: SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Key facts
- Where
- San Antonio, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05057806, who can take part
Where in United States
- University of Texas Health Science Center at San AntonioSan Antonio, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Trial code
- NCT05057806
- Record updated
- 6 April 2026
- Original description
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.Read full original descriptionShow less
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Inclusion: Type 2 Diabetes Mellitus; Class II-III New York Heart Association (NYHA) heart failure and reduced ejection fraction (EF) <50%; Age 18-80 years; BMI 23-38 kg/m2; Glycated hemoglobin (HbA1c) 5.5-10%; Blood Pressure (BP) ≤ 145/85 mmHg; Estimated glomerular filtration rate (eGFR) ≥30 ml/min•1.73 m2; Stable dose of guideline-directed medications for heart failure and Diabetes; Stable body weight (±4 pounds) over the last 3 months; Does not suffer from severe claustrophobia; No contraindication for MRI (metal plates, screws, shrapnel, pins, or cardiac pacemaker).
Exclusion: Subjects treated with an SGLT2 inhibitor, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or pioglitazone; Current drug or alcohol use or dependence; Allergy/sensitivity to study drugs or their ingredients; Cancer; Pregnancy, lactation or plans to become pregnant; Inability or unwillingness of individual or legal guardian/representative to give written informed consent.